



News Release

FOR IMMEDIATE RELEASE

Contact: Ronald Trahan, APR, Ronald Trahan Associates Inc., 508-359-4005, x108

Arterial Remodeling Technologies (“ART”) to disclose for the first time the novel design, and new data, for its potentially disruptive polymer-based bioresorbable stent

Data to be presented at EuroPCR 2011

“We will debunk the myth that polymer based stents are not optimal as a bioresorbable scaffold and validate that our bioresorbable stent represents disruptive technology.”

Machiel van der Leest, CEO

PARIS, May 17, 2011—[Arterial Remodeling Technologies](#) (“ART”) announced today that details of the state-of-the-art design of its potentially disruptive *polymer-based* bioresorbable stent platform will be revealed, for the first time, at EuroPCR 2011 from the podium tomorrow (Wednesday, May 18). The disclosure will be presented by **Antoine LaFont, M.D., Ph.D.**, Professor of Medicine, Head Interventional Cardiology Department, Georges Pompidou Hospital (Paris); and, Past Chairman, Interventional Cardiology Group, European Society of Cardiology (ESC). Dr. LaFont is a co-founder of ART.

Additionally, on Thursday, May 19, also at EuroPCR, Dr. LaFont will make a second presentation from the podium, disclosing additional data that further validates ART’s innovative approach to simultaneously balance biocompatibility, biomechanics and bioresorption in a bioresorbable PLA (polylactic acid) stent. These data will show that ART’s PLA-based stent can be **overexpanded by up to 25%** without any problems, thus avoiding the serious medical issues caused by cracking or malapposition.

“We will debunk the myth that polymer based stents are not optimal as a bioresorbable scaffold. Indeed, we have proven that overexpansion limitations are *technology* related and *most definitely not* related to the use of polymers in bioresorbable stents. Indeed, **this represents a seminal truth, that precise vessel-sizing at implantation is not necessary with our bioresorbable stent due to its crack- and malapposition-free overexpansion features,**” said **Machiel van der Leest**, CEO, who previously was a co-founder and Chief Technology Officer of Minvasys. During his career he has developed and

successfully introduced 15 Class III medical devices, which required pre-market approval and a scientific review to ensure safety and effectiveness.

“ART’s stent is designed to have several critically important competitive advantages over currently marketed and in-development bioresorbable stents, including that our stent is designed to have **(1) faster and smoother resorption**, and **(2) crack- and crazing-free expansion**—which are very significant competitive advantage for our bioresorbable stent,” explained van der Leest.

ART’s novel biopolymers have been developed in conjunction with one of the world’s leading authorities in polymer chemistry, Professor Michel Vert, who is Former Director of the Research Center for Artificial Biopolymers at France’s National Center for Scientific Research (Centre National de Recherche Scientifique/CNRS).

[About Arterial Remodeling Technologies \(“ART”\)](#)

Arterial Remodeling Technologies (“ART”) is developing bioresorbable coronary polymer stents that promote the natural remodeling of an injured artery after angioplasty. The Company’s technology is based on intellectual property originating from three esteemed institutions: the Cleveland Clinic; the French national research institute, CNRS (Centre National de Recherche Scientifique), Montpellier, France; and, Descartes University, Paris.

#####